uncovered a novel mechanism in which TRIM26 impedes the progression of clear cell renal cell carcinoma (ccRCC) by binding to and destabilizing ETK, which inhibits the proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT) of ccRCC cells, ultimately resulting in the deactivation of the AKT/mTOR signaling pathway. This evidence concerns the gene AKT1 and clear cell renal carcinoma.